petesher, I was thinking the exact same thing, so I made sure by...

petesher,

I was thinking the exact same thing, so I made sure by checking the facts:

From 28 August presentation:
(Refer Slide 25)
Headed "Outlook for Next 12 Months"
Section about halfway down the slide: "CHF- Significant Market Opportunity"
Second bullet point: "Interim analysis for safety/surrogate efficacy endpoints for HF-MACE"


From 25 November presentation:
(Refer Slide 32)
Headed "Upcoming Milestones"
Section on the diagram labelled MPC-150-IM
Second line in column headed "Anticipated Milestones"
"First Phase 3 interim analysis for safety and efficacy results in first half of 2016"

Looks like between a 4 month and a 10 month delay, depending on when in "first half 2016" it happens.

Given this - as MSB's flagship trial - was due to commence recruiting in 2012, I'd say that those are pretty liberal bounds, even for an industry with inherently long lead times.

Also, that the timeline has been delayed by the extent that it seemingly has - within just two months of the last update being provided - is disappointing, to say the very least.